López-Tarjuelo Juan, Morillo-Macías Virginia, Bouché-Babiloni Ana, Boldó-Roda Enrique, Lozoya-Albacar Rafael, Ferrer-Albiach Carlos
Servicio de Radiofísica y Protección Radiológica, Consorcio Hospitalario Provincial de Castellón, Avda. Dr. Clará, nº 19, Castellón de la Plana, 12004, Castellón, Spain.
Servicio de Oncología Radioterápica, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain.
Radiat Oncol. 2016 Mar 15;11:41. doi: 10.1186/s13014-016-0621-y.
Intraoperative electron radiotherapy (IOERT) is a highly selective radiotherapy technique which aims to treat restricted anatomic volumes during oncological surgery and is now the subject of intense re-evaluation. In vivo dosimetry has been recommended for IOERT and has been identified as a risk-reduction intervention in the context of an IOERT risk analysis. Despite reports of fruitful experiences, information about in vivo dosimetry in intraoperative radiotherapy is somewhat scarce. Therefore, the aim of this paper is to report our experience in developing a program of in vivo dosimetry for IOERT, from both multidisciplinary and practical approaches, in a consistent patient series. We also report several current weaknesses.
Reinforced TN-502RDM-H mobile metal oxide semiconductor field effect transistors (MOSFETs) and Gafchromic MD-55-2 films were used as a redundant in vivo treatment verification system with an Elekta Precise fixed linear accelerator for calibrations and treatments. In vivo dosimetry was performed in 45 patients in cases involving primary tumors or relapses. The most frequent primary tumors were breast (37 %) and colorectal (29 %), and local recurrences among relapses was 83 %. We made 50 attempts to measure with MOSFETs and 48 attempts to measure with films in the treatment zones. The surgical team placed both detectors with supervision from the radiation oncologist and following their instructions.
The program was considered an overall success by the different professionals involved. The absorbed doses measured with MOSFETs and films were 93.8 ± 6.7 % and 97.9 ± 9.0 % (mean ± SD) respectively using a scale in which 90 % is the prescribed dose and 100 % is the maximum absorbed dose delivered by the beam. However, in 10 % of cases we experienced dosimetric problems due to detector misalignment, a situation which might be avoided with additional checks. The useful MOSFET lifetime length and the film sterilization procedure should also be controlled.
It is feasible to establish an in vivo dosimetry program for a wide set of locations treated with IOERT using a multidisciplinary approach according to the skills of the professionals present and the detectors used; oncological surgeons' commitment is key to success in this context. Films are more unstable and show higher uncertainty than MOSFETs but are cheaper and are useful and convenient if real-time treatment monitoring is not necessary.
术中电子放疗(IOERT)是一种高度选择性的放疗技术,旨在在肿瘤手术期间治疗受限的解剖体积,目前正受到深入重新评估。体内剂量测定已被推荐用于IOERT,并在IOERT风险分析中被确定为一种降低风险的干预措施。尽管有成功经验的报道,但术中放疗体内剂量测定的信息仍较为匮乏。因此,本文旨在从多学科和实际应用的角度,在一组连续的患者中报告我们制定IOERT体内剂量测定方案的经验。我们还报告了当前存在的几个不足之处。
使用增强型TN-502RDM-H移动金属氧化物半导体场效应晶体管(MOSFET)和Gafchromic MD-55-2薄膜作为冗余的体内治疗验证系统,与Elekta Precise固定直线加速器配合进行校准和治疗。对45例涉及原发性肿瘤或复发的患者进行了体内剂量测定。最常见的原发性肿瘤是乳腺癌(37%)和结直肠癌(29%),复发患者中的局部复发率为83%。我们在治疗区域用MOSFET进行了50次测量尝试,用薄膜进行了48次测量尝试。手术团队在放射肿瘤学家的监督下并按照其指示放置了两种探测器。
参与的不同专业人员认为该方案总体上是成功的。使用以90%为规定剂量、100%为束流输送的最大吸收剂量的量表,用MOSFET和薄膜测量的吸收剂量分别为93.8±6.7%和97.9±9.0%(平均值±标准差)。然而,在10%的病例中,由于探测器未对准,我们遇到了剂量测定问题,通过额外检查可能避免这种情况。还应控制MOSFET的有效使用寿命长度和薄膜灭菌程序。
根据在场专业人员的技能和所使用的探测器,采用多学科方法为广泛的IOERT治疗部位建立体内剂量测定方案是可行的;在这种情况下,肿瘤外科医生的参与是成功的关键。薄膜比MOSFET更不稳定,不确定性更高,但更便宜,如果不需要实时治疗监测则有用且方便。